lundi 2 septembre 2019

Onco Actu du 2 septembre 2019


2.8 ETIOLOGIE - CONTRACEPTIFS, THS



Hormone therapy during menopause raises breast cancer risk for years, study finds [STAT]











Breast cancer risk from using HRT is ‘twice what was thought’ [The Guardian]










3.1 PRÉVENTION - TABAC



Anti-smoking advocates bemoan “faltering” pace of FDA action [AP]











The F.D.A.’s New Cigarette Warnings Are Disturbing. See for Yourself. [NY Times]











3.1.1 PRÉVENTION - TABAC - E-CIGS



The Mysterious Vaping Illness That’s ‘Becoming an Epidemic’ [NY Times]










Exclusive: India proposes ban on e-cigarettes, with jail terms for offenders - government documents [Reuters]











FTC probes marketing practices of e-cigarette maker Juul: source [Reuters]











CDC probes lung illnesses linked to e-cigarette use [Reuters]











E-cigarette firms probed over health concerns by U.S. House panel [Reuters]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Lack of government action on NHS staffing undermines ambition to diagnose cancer early [Cancer Research UK]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Prostate-imaging camera captures molecular detail to detect cancer [Stanford Medicine]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



U.S. Preventive Services Task Force Issues Final Recommendation Statement on BRCA-Related Cancer Prevention [USPSTF]











New Guidelines Expand BRCA Screening [The Scientist]










5. TRAITEMENTS



Roche's effort to stop cancer metastasis unexpectedly leads to a Merck drug [Fierce Biotech]











5.10 TRAITEMENTS - ESSAIS



Many clinical trials for new cancer drugs didn’t include any data on race [STAT]











A Double Whammy of Non-Good News About Non-Inferiority Trials [Absolutely Maybe]











FDA finalizes guidance on placebos and blinding for cancer trials [EndPoints]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Celgene pays Immatics $75M to work on solid tumor cell therapies [Fierce Biotech]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Adaptimmune pens backloaded deal to access T-cell tech [Fierce Biotech]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



AstraZeneca's Imfinzi-tremelimumab duo flops another late-stage lung cancer trial [Fierce Pharma]










AstraZeneca lung cancer miss is Merck's gain [Biopharma Dive]











Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer [AstraZeneca]











AstraZeneca’s Imfinzi/treme combo strikes out — again — in lung cancer. Is it time for last rites? [EndPoints]











AstraZeneca Imfinzi combination fails advanced lung cancer study [Reuters]











5.12.6 IMMUNOTHÉRAPIES - AMM



Roche's Tecentriq grabs I-O's first European OK for triple-negative breast cancer [Fierce Pharma]











EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer [EndPoints]











Roche immunotherapy Tecentriq gains European approval for breast cancer [Reuters]











European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer [Roche]











5.13 WCLC



Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer [Merck]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



Why a Promising, Potent Cancer Therapy Isn't Used in the US [Wired]











5.2.1 PHARMA - PARTENARIATS



Presage inks its 3rd deal around phase 0 studies—with more to come [Fierce Biotech]










Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps [EndPoints]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



When it comes to cancer drug deals, one hot protein family is raking in billions: report [Fierce Pharma]











5.2.4 PHARMA - ABBVIE



It's official—AbbVie dumps Rova-T after another lung cancer fail [Fierce Biotech]










AbbVie ends Rova-T research after another study setback [Biopharma Dive]











AbbVie abandons late-stage lung cancer asset Rova-T [Reuters]











AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program [AbbVie]











5.2.5 PHARMA - GSK



Moving quickly, GSK to advance myeloma drug on new data [Biopharma Dive]










GSK's Hal Barron heralds their second positive pivotal for crucial anti-BCMA therapy, pointing to a push for quick OKs in a crowded field [EndPoints]











GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma [GSK]











GSK builds oncology pipeline as drug shown to help myeloma patients [Reuters]











5.3 TRAITEMENTS - FDA, EMA, NICE...



EMA and FDA historically agree on just about every new drug approval, but is that slowly changing? [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Janssen Announces European Commission Approval of Imbruvica®▼(ibrutinib) for Expanded Use in Two Indications [Janssen]











European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma [BMS]











Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen [EndPoints]











FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor [FDA]











Roche's personalized cancer treatment wins FDA approval [Reuters]











FDA approves Celgene's bone marrow cancer treatment [Reuters]











Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi [Reuters]











5.4 TRAITEMENTS - ECONOMIE



Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [NICE]











6. LUTTE CONTRE LES CANCERS



For a decade, Francis Collins has shielded NIH—while making waves of his own [Science]











6.1 OBSERVATION



Childhood cancer survivors face variety of heart risks [Reuters]











As Americans get heavier, obesity-linked cancers may strike earlier [Reuters]










6.10 POLITIQUES



The Government has announced it will establish a new Cancer Control Agency by the end of the year [Science Media Center]











6.11 PATIENTS



The Emperor of All Maladies’ New Clothes [NY Times]











6.6 PUBLICATIONS



More than 700 German research institutions strike open-access deal with Springer Nature [Science]











In departure for NIH, Cancer Moonshot requires grantees to make papers immediately free [Science]











6.7.1 IA/BIOINFORMATIQUE



The “inconvenient truth” about AI in healthcare [Digital Medicine]










6.9 CONTROVERSES



Scientists Avoid Bias When They Know They're Being Tested [Wired]